WebMacitentan (Opsumit(®)) is an orally active, dual endothelin receptor antagonist (ERA) with tissue targeting properties. Macitentan was approved recently in the EU (as … WebMacitentan, sold under the brand name Opsumit, is an endothelin receptor antagonist (ERA) developed by Actelion and approved for the treatment of pulmonary arterial hypertension (PAH). The other two ERAs marketed as of 2014 are bosentan and ambrisentan. Macitentan is a dual ERA, meaning that it acts as an antagonist of two …

U.S. Food and Drug Administration

WebOct 26, 2024 · Macitentan Brand name: Opsumit Drug class: Vasodilating Agents Chemical name: N- [5- (4-Bromophenyl)-6- [2- [ (5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N′-propyl-sulfamide Molecular formula: C 19 H 20 Br 2 N 6 O 4 S CAS number: 441798-33-0 Medically reviewed by Drugs.com on Oct 26, 2024. Written by ASHP. Introduction Uses … oxford high school michigan greatschools

FC Martinenc - Wikipedia

Web(macitentan) tablets, for oral use Initial U.S. Approval: 2013 . WARNING: EMBRYO-FETAL TOXICITY . See full prescribing information for complete boxed warning • Do not administer OPSUMIT to a pregnant female because it may cause fetal harm .1, 5.1, 8.1) . • Females of reproductive potential: exclude pregnancy before WebApr 1, 2024 · Macitentan works by relaxing these blood vessels and increasing the supply of blood to the lungs, which reduces the workload of the heart. This medicine is available … WebOPSUMIT ® (macitentan) Risk Evaluation and Mitigation Strategy (REMS) A REMS program is required by the US Food and Drug Administration (FDA) to manage serious risks associated with a drug product. All healthcare providers must enroll in Opsumit® REMS and comply with its requirements for prescribing OPSUMIT®. jeff horton chipley